Upregulation of Thrombospondin 1 Expression in Synovial Tissues and Plasma of Rheumatoid Arthritis: Role of Transforming Growth Factor-β1 toward Fibroblast-like Synovial Cells

J Rheumatol 2017;44;131
http://www.jrheum.org/content/44/1/131

1. Sign up for TOCs and other alerts
   http://www.jrheum.org/alerts

2. Information on Subscriptions
   http://jrheum.com/faq

3. Information on permissions/orders of reprints
   http://jrheum.com/reprints_permissions

The Journal of Rheumatology is a monthly international serial edited by Earl D. Silverman featuring research articles on clinical subjects from scientists working in rheumatology and related fields.
Correction

Upregulation of Thrombospondin 1 Expression in Synovial Tissues and Plasma of Rheumatoid Arthritis: Role of Transforming Growth Factor-β1 toward Fibroblast-like Synovial Cells


In Figure 3, panel B, the unit of measurement was incorrect. The corrected figure is reprinted below. In addition, in the second paragraph of the Results section, the representative results for thrombospondin 1 associated with circulating immune complexes in the culture supernatants of each stimulated fibroblast-like synovial cell should be in ng/ml. In the fourth paragraph, the unit for transforming growth factor-β1 at baseline and after induction of new treatment should be ng/ml.

doi:10.3899/jrheum.141292.C1

Figure 3. Correlations between Δvalues in plasma TSP-1 and those in (A) DAS28-ESR, (B) plasma TGF-β1, (C) serum IL-6, and (D) serum VEGF after introduction of DMARD therapies (n = 16). The Spearman rank correlation coefficient and the corresponding p value are shown above each scatter plot. TSP-1: thrombospondin 1; DAS28: 28-joint Disease Activity Score; ESR: erythrocyte sedimentation rate; TGF-β1: transforming growth factor-β1; IL-6: interleukin 6; VEGF: vascular endothelial growth factor; DMARD: disease-modifying antirheumatic drugs.